Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical estradiol inhibits hair growth in mice by preventing the hair follicle's transition from resting to growth phase, a process reversible with an estrogen receptor antagonist.

This study found that the effectiveness of 17-beta-estradiol in inhibiting hair growth depends on its application method, and noted significant sex differences in response to 17-alpha-estradiol in male and female mice.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

This study found that patients receiving immune checkpoint inhibitors who have a history of psoriasis are at a higher risk for developing gastrointestinal and endocrine toxicities within one year compared to those without psoriasis.

This paper reports insights from an Expert Panel convened by the Society for Immunotherapy of Cancer on managing immune-related adverse events (irAEs) following immune checkpoint inhibitor therapy, highlighting surveillance gaps and the need for a comprehensive irAE registry to improve post-treatment care for cancer survivors.

In this study, researchers found that mitochondrial complex I plays a crucial role in regulating innate immunity and bone remodeling, with Ndufs4 deletion causing systemic inflammation and osteopetrosis through various metabolic shifts and cellular mechanisms.

This study found that 17-beta-estradiol inhibits hair growth in mice by blocking hair follicles in the telogen phase, whereas an estrogen receptor antagonist promotes hair growth by initiating anagen.

This study found that estrogen receptor beta plays a significant role in murine hair growth control, potentially acting as a silencer of estrogen receptor alpha's catagen-promoting effects.

This study found that 17β-estradiol inhibited RANTES production in human keratinocytes by suppressing nuclear factor κB activity, suggesting a potential mechanism for 17β-estradiol's modulation of psoriasis-related inflammation.

This study demonstrates that locally synthesized estrogen and androgen neurosteroids play opposite roles in long-term synaptic changes in male rats' medial vestibular nucleus, with testosterone-dihydrotestosterone mediating long-term depression and 17β-estradiol mediating long-term potentiation.

This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.

This laboratory study concluded that TRPA1 and TRPV1 channels do not play a role in mechanotransduction processes in slowly adapting type II mechanoreceptors in isolated rat sinus hair follicles.

This review discusses the characteristics and treatment recommendations for skin-related adverse effects from immune checkpoint inhibitors in cancer treatment, and notes an observed association with favorable oncology outcomes that requires careful interpretation.

This study did not find any significant effects of estradiol or its antagonists on hair growth in two common mouse strains, challenging previous results reported by Oh and Smart.

This study reports the development of a novel protocol to purify human TRPV3 ion channels, revealing functional properties and differences in ligand interactions, enabling further structural and functional research.

This study found that oxybenzone is very stable under light exposure, contradicting previous findings of its oxidation to semiquinone after solar irradiation.

This review discusses the characteristics and management of cutaneous immune-related adverse events from immune checkpoint inhibitors and notes their potential association with a favorable cancer treatment response.

This study suggests that estrogen regulates vitamin A metabolism in skin tissues in a sex-dependent manner, which may have implications for treating acne, hair loss, and skin immunity.

This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.

In this study, among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, 1.33% developed scarring alopecia, all being female, with alopecia not impacting their cancer treatment continuation and a favorable cancer outcome reported.

In this case series, researchers reported scarring alopecia in six out of 450 patients (1.33%) treated with immune checkpoint inhibitors for metastatic melanoma, with all affected patients experiencing other immune-related adverse effects but continuing treatment with favorable cancer outcomes.

In this study, researchers reported a 1.33% prevalence of scarring alopecia among 450 patients treated with immune checkpoint inhibitors for metastatic melanoma, noting that hair loss did not require treatment discontinuation and seemed to coincide with favorable cancer outcomes.

This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.

This study found that estradiol affects hair growth in mice by regulating the transition of hair follicles from rest to growth phases via the estrogen receptor pathway in the dermal papilla.

This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.

This study found that β-sitosterol, a brain-penetrable phytosterol, reduced melanoma cell growth and brain metastasis formation by interfering with mitochondrial respiration, suggesting its potential as an adjuvant therapy to BRAF inhibitors for patients with melanoma brain metastases.

This study concludes that combining chemotherapy with immune checkpoint inhibitors is additive rather than synergistic in terms of adverse events for advanced non-small cell lung cancer patients.

This review discusses recent findings on the mechanisms driving bullous pemphigoid, highlighting epitope spreading and the roles of regulatory T cells, and reports no new experimental results.

This review explores the current applications and expanding indications of platelet-rich plasma in dermatology and cosmetic dermatology, but reports no new clinical results.

This review discusses the role of nurse navigators in managing polycystic ovary syndrome, highlighting their support in symptom management, lifestyle changes, psychosocial care, and evidence-based practices, but presents no new findings.